Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) — NFD

Nephrogenic Systemic Fibrosis Clinical Trial

Official title:
Use of Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) and Understanding Its Etiology

Status Terminated

Clinical Trial Summary

The purpose of this study is to evaluate the pathophysiology of nephrogenic fibrosing dermopathy (NFD)/nephrogenic systemic fibrosis (NSF).

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01078987
Study type	Interventional
Source	Loma Linda University
Contact
Status	Terminated
Phase	Phase 4
Start date	February 2002
Completion date	March 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00981942` - Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec	Phase 3
Completed	`NCT01135316` - Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR	N/A
Active, not recruiting	`NCT00677092` - Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis	Phase 2
Completed	`NCT00869479` - Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis	N/A
Enrolling by invitation	`NCT01359345` - Nephrogenic Systemic Fibrosis With Gadollinum	Phase 2/Phase 3
Withdrawn	`NCT00811863` - Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection	N/A
Completed	`NCT01014754` - Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels	N/A